Skip to content
Screener

CG Oncology CGON Enterprise value

Enterprise value at other companies

Pfizer logo
PfizerPFE
$222.4B+9.2%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$639.97B+60.7%
Gilead Sciences logo
Gilead SciencesGILD
$179.93B+17.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$8.16B+187%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$361.36M+31.6%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$163.63M-76.9%

Other financials

Income statement

See full
Revenue$1.2M
Operating income-$86.4M-77.3%
Net income-$79.1M-90.8%
EPS (diluted)-$0.90-66.7%

Balance sheet

See full
Cash & equivalents$19.6M+34.3%
Total debt$8.8M+787%
Total equity$1.0B+53.5%
Total assets$1.1B+54.8%

Cash flow

See full
Operating cash flow-$46.4M-66.0%
CapEx$468.0K+3,243%
Free cash flow-$46.9M-67.6%

Valuation

See full
Market cap$6.6B+242%
P/S1,060×-2,439×

Profitability

See full
Operating margin-4,056.2%-1,873pp
Net margin-3,602.7%-1,650pp
FCF margin-2,879.6%-1,307pp

Returns & leverage

See full
Return on equity-26.4%+9.3pp
Debt / equity0.0×
Current ratio22.2×+0.1×

Where this comes from

Calculated from CG Oncology’s reported figures.

The source filing: CG Oncology’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 8:45 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336918

FAQ

What is CG Oncology's enterprise value?
CG Oncology (CGON) reported enterprise value of $6.26B in Q2 2026.
How has CG Oncology's enterprise value changed year-over-year?
CG Oncology's enterprise value increased by 220.3% year-over-year, from $1.95B to $6.26B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Ask your AI about CG Oncology's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude